Bristol BioDesign Institute - BrisSynBio - Flexible Talent Mobility Account

Lead Research Organisation: University of Bristol
Department Name: Biochemistry

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description The two BioDesign Innovation Fellowships have underpinned the formation of two new SynBio start-ups: Phase Biolabs and Mechanised Biosystems Seven Early Career Researchers have benefitted from secondments in synthetic biology SMEs or in pre-spin out synthetic biology projects, three of whom have been recruited to permanent positions by their host SMEs, and one of whom has been recruited to a new synthetic biology SME. The SMEs make a significan contribution to the local economy, collectively raising over £16M and creating more than 50 jobs to date. The impact of the additional funds beyond those of the original award are: 1. An inward Innovation Placement for a researcher who moved from Italy to Bristol to work on commerically relevant research contributig to the spin out of Rosa Biotech, which has raised £750k of angel funding. 2. Outward Innovation Placements that have been instrumental in the growth and development of Bristol-based synthetic biology ecosystem (CytoSeek, Imophoron, Scarlet Therapeutics, Zentraxa). 3. Graduation of two BioDesign Innovation fellows, who between then have encorporated 4 companies (Phase Biolabs, RapiFarm, testbuds.io, and Mechanised Biosystems) 4. Science Entrepreneur Experience training, which trained 11 synthetic biology PhDs and ECRs from Bristol.
First Year Of Impact 2020
Sector Aerospace, Defence and Marine,Healthcare,Manufacturing, including Industrial Biotechology
Impact Types Societal

 
Description Best of the West: HLS Accelerator
Amount £496,443 (GBP)
Funding ID 10076253 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 04/2023 
End 12/2023
 
Description BrisEngBio: From Synthetic to Engineering Biology at Bristol
Amount £1,517,913 (GBP)
Funding ID BB/W013959/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2022 
End 01/2024
 
Description CytoSeek 
Organisation CytoSeek
Country United Kingdom 
Sector Private 
PI Contribution ECR
Collaborator Contribution ECR career development and training in a synthetic biology SME
Impact ECR career development and training in a synthetic biology SME
Start Year 2019
 
Description Imophoron 
Organisation Imophoron Ltd
Country United Kingdom 
Sector Private 
PI Contribution ECR
Collaborator Contribution ECR career development and training in a synthetic biology SME
Impact ECR career development and training in a synthetic biology SME
Start Year 2019
 
Description Lab Genius 
Organisation LabGenius
Country United Kingdom 
Sector Private 
PI Contribution ECR
Collaborator Contribution ECR career development and training in a synthetic biology SME
Impact ECR career development and training in a synthetic biology SME
Start Year 2019
 
Description Rosa Biotech 
Organisation Rosa Biotech Limited
Country United Kingdom 
Sector Private 
PI Contribution ECR
Collaborator Contribution ECR career development and training in a synthetic biology SME
Impact ECR career development and training in a synthetic biology SME
Start Year 2019
 
Description Zentraxa 
Organisation Zentraxa Ltd
Country United Kingdom 
Sector Private 
PI Contribution ECR
Collaborator Contribution ECR career development and training in a synthetic biology SME
Impact ECR career development and training in a synthetic biology SME
Start Year 2019
 
Company Name CytoSeek 
Description CytoSeek develops cell membrane augmentation technology, with applications in cell therapies for various disorders. 
Year Established 2017 
Impact None yet
Website https://www.cytoseek.uk/
 
Company Name Imophoron 
Description Imophoron develops a range of therapeutics. 
Year Established 2017 
Impact Press release issued: 7 October 2021 Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Website https://www.imophoron.com/
 
Company Name Phase Biolabs 
Description Phase Biolabs develops biotechnology for converting waste carbon dioxide into carbon neutral products including e-fuels. 
Year Established 2020 
Impact To early to say
Website https://www.phasebiolabs.com/
 
Company Name Rosa Biotech 
Description Rosa Biotech develops artificially intelligent biosensing tools based on nano-scale peptide barrels, with applications in industrial research and clinical diagnostics. 
Year Established 2019 
Impact None yet
Website http://www.rosabio.tech
 
Company Name Scarlet Therapeutics 
Description Scarlet Therapeutics develops engineered red blood cell-based therapeutics for a range of disease applications. 
Year Established 2021 
Impact None yet
Website https://scarlet-tx.com/
 
Company Name Zentraxa 
Description Zentraxa operates a synthetic biology platform that designs, produces and tests novel peptides, which can then be used to treat human diseases. 
Year Established 2017 
Impact Applcations in medial and industrial adhesives and personal care.
Website http://zentraxa.com
 
Company Name Loop Research Labs Ltd 
Description  
Year Established 2020 
Impact To early to say